Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 4:21 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 22,371 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Immune Clear all
Completed Phase 2 Interventional Results available

A Study to Assess Long-term Safety, Tolerability and Efficacy of Rozanolixizumab in Subjects With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

NCT04051944
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
Interventions
Rozanolixizumab
Drug
Lead sponsor
UCB Biopharma SRL
Industry
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
4
States / cities
Scottsdale, Arizona • Augusta, Georgia • Charlotte, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2022 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

NCT00569309
View directory record Official record
Conditions
Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Small Intestine Cancer
Interventions
Streptococcus pneumoniae, laboratory correlative studies, quality-of-life assessment
Biological · Other
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer

NCT00004232
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Graft Versus Host Disease, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition
Interventions
filgrastim, cyclosporine, methylprednisolone, prednisone, allogeneic bone marrow transplantation, peripheral blood stem cell transplantation
Biological · Drug · Procedure
Lead sponsor
Northwestern University
Other
Eligibility
10 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2012 · Synced Oct 29, 2026, 4:21 AM EDT
Active, not recruiting Phase 2 Interventional

A Clinical Study Evaluating a Combination of Oregovomab and Niraparib in Adult Women With Platinum Sensitive Recurrent Ovarian Cancer.

NCT05335993
View directory record Official record
Conditions
Recurrent Ovarian Cancer, Recurrent Epithelial Cancer of Ovary, Recurrent Epithelial Ovarian Cancer, Recurrent Fallopian Tube Cancer, Peritoneal Cancer, Recurrent Carcinoma of Ovary, Adenocarcinoma of Ovary
Interventions
Oregovomab, Niraparib
Biological · Drug
Lead sponsor
CanariaBio Inc.
Industry
Eligibility
18 Years to 99 Years · Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
3
States / cities
Durham, North Carolina • Oklahoma City, Oklahoma • Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 3, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Recruiting Not applicable Interventional

Smart Inhaler and Remote Asthma Management in Adolescents With Intellectual and Developmental Disabilities

NCT07746921
View directory record Official record
Conditions
Asthma in Children, Intellectual Disabilities (F70-F79), Developmental Disability, Autism Spectrum Disorder
Interventions
Use of active remote smart inhaler in the home setting, Use of passive remote smart inhaler in the home setting
Behavioral
Lead sponsor
Children's Hospital Los Angeles
Other
Eligibility
10 Years to 17 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

CDDO to Treat Solid Tumors and Lymphomas

NCT00322140
View directory record Official record
Conditions
Solid Tumors, Lymphoma
Interventions
CDDO
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Treatment for Depression Among HIV-Infected Youth

NCT01049789
View directory record Official record
Conditions
HIV, Depression, HIV Infections
Interventions
COMB - Combination Cognitive Behavioral Therapy and Medication Management, TAU - Treatment as Usual
Behavioral
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
16 Years to 24 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
4
States / cities
Tampa, Florida • The Bronx, New York • Philadelphia, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Three-way, Cross-over Closed-loop Exercise Study

NCT02241889
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Insulin pump therapy, Closed-loop Artificial Pancreas Controller
Device
Lead sponsor
Oregon Health and Science University
Other
Eligibility
21 Years to 45 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated May 22, 2017 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

A Study of the Safety and Efficacy of Tofimilast in Adult Asthmatics

NCT00150397
View directory record Official record
Conditions
Asthma
Interventions
Tofimilast
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005
U.S. locations
16
States / cities
Encinitas, California • Riverside, California • DeLand, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2012 · Synced Oct 29, 2026, 4:21 AM EDT
Active, not recruiting Not applicable Interventional Results available

SP Thoracic IDE Study

NCT05150210
View directory record Official record
Conditions
Primary Lung Cancer, Benign Lung Disease, Thymoma, Myasthenia Gravis
Interventions
Robotic-Assisted Surgery
Device
Lead sponsor
Intuitive Surgical
Industry
Eligibility
21 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Activity and Nutrition Trial in Lupus to Energize and Renew

NCT02281513
View directory record Official record
Conditions
Systemic Lupus Erythematosus, Physical Activity, Sleep
Interventions
Smartphone Application, Fitbit Activity Monitor, Coaching Sessions
Other
Lead sponsor
Northwestern University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 13, 2023 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

An Extension Study of AK002 in Patients With Eosinophilic Gastritis and/or Eosinophilic Duodenitis

NCT03664960
View directory record Official record
Conditions
Eosinophilic Gastritis, Eosinophilic Gastroenteritis, Eosinophilic Duodenitis
Interventions
AK002
Drug
Lead sponsor
Allakos Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Ventura, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2024 · Synced Oct 29, 2026, 4:21 AM EDT
Terminated Phase 1 Interventional

A Study of CG-806 in Patients With Relapsed or Refractory CLL/SLL or Non-Hodgkin's Lymphomas

NCT03893682
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Non-Hodgkin's Lymphoma
Interventions
CG-806
Drug
Lead sponsor
Aptose Biosciences Inc.
Industry
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
30
States / cities
Los Angeles, California • Monterey, California • Redondo Beach, California + 25 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 2 Interventional Results available

Efficacy and Safety Study of Idelalisib in Participants With Indolent B-Cell Non-Hodgkin Lymphomas

NCT01282424
View directory record Official record
Conditions
Follicular Lymphoma, Small Lymphocytic Lymphoma, Lymphoplasmacytic Lymphoma, Marginal Zone Lymphoma
Interventions
Idelalisib
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
125 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
22
States / cities
Fullerton, California • Long Beach, California • Los Angeles, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2019 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

NCT00439361
View directory record Official record
Conditions
Hodgkin Lymphoma, Lymphoma
Interventions
Bortezomib, Carboplatin, Etoposide, Ifosfamide, Mesna
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
16 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2012 · Synced Oct 29, 2026, 4:21 AM EDT
Terminated Not applicable Interventional Accepts healthy volunteers Results available

A Couples-based Intervention for Transgender Women and Their Partners

NCT04067661
View directory record Official record
Conditions
HIV Infections, HIV Primary Infection
Interventions
CHIP, Control
Behavioral
Lead sponsor
University of Michigan
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Not applicable Interventional

Study of Total Body Irradiation and Fludarabine Followed By Allogeneic Peripheral Blood Stem Cell or Bone Marrow Transplantation in Combination With Cyclosporine and Mycophenolate Mofetil in Patients With Inherited Disorders

NCT00010361
View directory record Official record
Conditions
Metabolism, Inborn Errors, Granulomatous Disease, Chronic
Interventions
cyclosporine, fludarabine, mycophenolate mofetil
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
Up to 55 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 9, 2014 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 3 Interventional Results available

A Study Testing the Superiority of CHF 1535 pMDI 800/24µg Total Daily Dose Compared With CHF 718 pMDI 800µg Total Daily Dose in Adults With Asthma on Medium or High-Dose Inhaled Corticosteroid

NCT05292586
View directory record Official record
Conditions
Asthma
Interventions
Beclomethasone Dipropionate/Formoterol Fumarate, Beclomethasone Dipropionate
Drug
Lead sponsor
Chiesi Farmaceutici S.p.A.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
91
States / cities
Mobile, Alabama • Chandler, Arizona • Encinitas, California + 65 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 4 Interventional Results available

RESTART C0168Z05 Rheumatoid Arthritis Study

NCT00714493
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
Infliximab
Biological
Lead sponsor
Centocor Ortho Biotech Services, L.L.C.
Industry
Eligibility
18 Years and older
Enrollment
203 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
45
States / cities
Huntsville, Alabama • Paradise Valley, Arizona • Tucson, Arizona + 42 more
Source: ClinicalTrials.gov public record
Updated Sep 12, 2013 · Synced Oct 29, 2026, 4:21 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Prevalence of Decreased Corneal Sensation in Patients With Chronic Inflammatory Demyelinating Polyneuropathy

NCT01379833
View directory record Official record
Conditions
Chronic Inflammatory Demyelinating Polyneuropathy
Interventions
Not listed
Lead sponsor
State University of New York at Buffalo
Other
Eligibility
18 Years to 110 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Oct 29, 2026, 4:21 AM EDT
Completed No phase listed Observational

Psychometric Validation of Cognitive Endpoints

NCT01335633
View directory record Official record
Conditions
Multiple Sclerosis
Interventions
Not listed
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
4
States / cities
Teaneck, New Jersey • West Orange, New Jersey • Buffalo, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 2 Interventional

Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

NCT01337752
View directory record Official record
Conditions
Multiple Myeloma, Renal Insufficiency
Interventions
BHQ880, BHQ880 Placebo, bortezomib, dexamethasone
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
55 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
2
States / cities
Chicago, Illinois • Spokane, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Not applicable Interventional Results available

PROFAST Intervention in Precursor Multiple Myeloma

NCT05565638
View directory record Official record
Conditions
Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS, Fasting, Multiple Myeloma
Interventions
Prolonged Fasting Intervention, EDUCATION CONTROL
Behavioral
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 29, 2026, 4:21 AM EDT
Completed Phase 1 Interventional

Foscarnet Treatment of Serious CMV Retinitis Infection in Patients With Acquired Immunodeficiency Syndrome

NCT00000726
View directory record Official record
Conditions
Cytomegalovirus Retinitis, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 65 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1992
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Oct 29, 2026, 4:21 AM EDT